Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 18/20 | 0.58 |
| ▸ | PTGFR | P43088 | 8/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138213 | 0.89 | PTGER3 (0.56) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137695 | 0.88 | PTGER3 (0.58) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137899 | 0.85 | PTGER3 (0.60) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137616 | 0.85 | PTGER3 (0.68) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137610 | 0.85 | PTGER3 (0.68) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137788 | 0.83 | ALDH1A1 (0.43) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137690 | 0.81 | PTGER3 (0.61) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1138112 | 0.81 | PTGER3 (0.61) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137602 | 0.81 | PTGER3 (0.63) | PTGER3PTGFRPTGER2PTGER4PTGER1 | |
| SCHEMBL1137605 | 0.81 | PTGER3 (0.63) | PTGER3PTGFRPTGER2PTGER4PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | disclosed |
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-7598397-B2 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | DECODE GENETICS EHF (IS) | 2009-10-06 | — | — | US | disclosed |
| EP-1814881-A2 | CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1812388-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006044415-A2 | CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | PTGER3 19/4885PTGFR 11/4885PTGER2 18/4885 |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, PTGS2 | PTGER3 19/4885PTGFR 11/4885PTGER2 18/4885 |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGDR | PTGER3 19/4885PTGFR 4/4885PTGER2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.